L

Lannett Company Inc
F:LN5

Watchlist Manager
Lannett Company Inc
F:LN5
Watchlist
Price: 2.254 EUR Market Closed
Market Cap: 24.3m EUR

EV/EBITDA
Enterprise Value to EBITDA

-17
Current
-16.9
Median
13.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-17
=
Enterprise Value
533m EUR
/
EBITDA
-36m USD
EBITDA Growth EV/EBITDA to Growth
US
L
Lannett Company Inc
F:LN5
Average EV/EBITDA: 434.3
Negative Multiple: -17
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.7
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.4
7%
1.9
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
112.7
10%
11.3
CH
Novartis AG
SIX:NOVN
9.9
5%
2
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
13%
0.7
US
Merck & Co Inc
NYSE:MRK
7.9
7%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A